Key facts
- ExoNeuglia’s last known valuation is $46.8M (Dec 2022).
- It has raised $7.0M; the latest was Early Stage VC in Aug 2025.
- Notable investors include Ascentage Pharma, Grains Valley Venture Capital, Redhill Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for ExoNeuglia
- ·The full record, as it builds
Funding rounds
No funding rounds for ExoNeuglia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ExoNeuglia
Developer of nervous system-related stem cell drugs intended to treat demyelinating diseases. The company uses induced pluripotent stem cell technology to develop medicines to treat demyelinating diseases, helping patients with loss of myelin in the nervous system and conditions such as spinal cord injury, multiple sclerosis, Guillain-Barré syndrome, neuromyelitis optica, etc.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2022
- Website
- exoneuglia.com/
- Ownership
- Privately Held (backing)
ExoNeuglia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ExoNeuglia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ExoNeuglia in its N-PORT filings yet. We sweep new filings monthly.